ANI Pharmaceuticals Inc (ANIP)

ANI Pharmaceuticals Inc's gross profit margin has shown some fluctuations over the past five years. In December 2020, the gross profit margin was at 58.19%, indicating that the company was able to generate a profit of 58.19 cents for every dollar of revenue after deducting the cost of goods sold.

By December 2021, the gross profit margin decreased to 53.45%, suggesting that the company's profitability from its core operations had declined. However, by December 2022, there was an improvement in the gross profit margin to 56.13%, indicating better cost management or potentially increased pricing power.

In December 2023, the gross profit margin significantly increased to 62.71%, signaling a higher level of profitability from the company's core business activities. This improvement could be due to cost efficiencies, increased sales volume, or better pricing strategies.

Surprisingly, by December 2024, the gross profit margin surged to 100.00%. While achieving a gross profit margin of 100% is rare and may raise questions about data accuracy or the company's operations, it could also be attributed to unique accounting circumstances such as a one-time event, a change in the company's business model, or other factors that require further investigation and clarification.

In conclusion, ANI Pharmaceuticals Inc's gross profit margin has varied over the years, with fluctuations suggesting changes in the company's ability to generate profits from its core operations. It is essential to further analyze the underlying reasons behind these fluctuations to assess the company's overall financial performance accurately.

Peer comparison

Dec 31, 2024